While treatments for melanoma have been steadily improving over recent years, patients with brain metastases have consistently had poor outcomes.…
Browsing: Melanoma and Skin
A variety of new therapeutics for melanoma are on the horizon, including IDO, immune checkpoint, LAG-3 and HDAC inhibitors. Here,…
The treatment of melanoma is undergoing exciting advancements, as discussed here by Paolo Ascierto, MD, of the National Cancer Institute…
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, hosted an array of exciting clinical trials…
Paul Nghiem, MD, PhD, University of Washington, shares MCC Needs to be Managed in Multidisciplinary Way | Oncology, Surgery, Radiation…
Paul Nghiem, MD, PhD, University of Washington, shares Patients Who Dont Respond to Checkpoint Therapy | Collaborating to Pick Apart…
Paul Nghiem, MD, PhD, University of Washington, shares Collaborative Community Working to Understand MCC | Do Not Need Mutational Burden…
Paul Nghiem, MD, PhD, University of Washington, shares Cannot Predict Who Responds to Immunotherapies | Response is 60% or More…
Paul Nghiem, MD, PhD, University of Washington, shares Immunotherapy better than Chemo-Therapy More Durable, Works Better in the Frontline at…
Paul Nghiem, MD, PhD, University of Washington, shares Immunotherapy & Chemo-Therapy with MCC Response is 60% or More If therapy…
Eric A. Klein, MD, Cleveland Clinic, explains The Circulating Cell-free Genome Atlas Study | Hope to Develop Multi-Cancer Screening Test…
Paul Nghiem, MD, PhD, University of Washington, explains Avelumab, for Metastatic Merkel Cell Carcinoma | Observed Responses are Durable at…
From the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO, Jacob Kettle, PharmD, BCOP, of the University…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about Adjuvant Data Changing Clinical Practice Moving into Anti-PD-1 monotherapy, and…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, shares Economics Outcome Research More Important Guiding clinicians & policy makers, survival…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Safety Profile of Once-Weekly Regimen Was comparable opposed to…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about ECOG-ACRIN EA6134 Ipilimumab + Nivolumab vs. Dabrafenib + Trametinib at…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, shares Economic Outcome Analysis for BRAF Melanoma Anti-CD4+PD-1, & Anti-PD-1 both followed…